Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease

• Conditions: Right Ventricular Dysfunction; COPD; Pulmonary Vascular Disorder

• Registration Number: NCT03184727
• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Brief Summary

The pulmonary vasculopathy and right heart dysfunction in COPD are drawing increasing attention these days. Recent researches show that pulmonary vasculopathy and right heart dysfunction relate to greater severity in COPD. Applying appropriate modalities for early detection of pulmonary vasculopathy and right heart dysfunction is of great importance. What's more, the interaction mechanism between pulmonary vasculature, right heart and COPD still needs to be further studied. The aim of our study is to develop an assessment system of pulmonary vasculopathy and right heart dysfunction in COPD patients and elucidate their impact on COPD course and outcome.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-06
• Study First Submitted: 2017-06-08
• Study First Submitted QC: 2017-06-10
• Last Update Submitted: 2017-06-13
• Study First Posted: 2017-06-14
• Last Update Posted: 2017-06-14
• Study Start: 2017-06-15
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• stable COPD patients

Exclusion Criteria

• patents with other respiratory diseases and pulmonary hypertension other than group 3 PH;
• psychopath, addict or patients not able to coordinate;
• patients in pregnancy or breastfeeding;
• patients with limited life expectancy;
• patients with contraindiction for MRI or PET;
• patients having cerebrovascular events in 3 months;
• unstable COPD patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality	3 years	survival rate in %

Secondary Outcome Measures

Name	Time	Method
COPD exacerbations	3 year	total times
GOLD degree	3 year	Ⅰ-Ⅳ according to the pulmonary function
NYHA degree	3 year	Ⅰ-Ⅳ according to the symptom

Trial Locations

Locations (1)

Cardiovascular Institute and Fu Wai Hospital; 🇨🇳 Beijing, Beijing, China